Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | KIF11 | P52732 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020408 | 1.00 | KCNH2 (0.69) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL2020058 | 0.92 | KCNH2 (0.69) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL2020053 | 0.92 | KCNH2 (0.69) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| Np-10679 SCHEMBL2018279 | 0.91 | KCNH2 (0.80) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| Np-10679 SCHEMBL30228906 | 0.91 | KCNH2 (0.80) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| Np-10679 SCHEMBL2018281 | 0.91 | KCNH2 (0.80) | KCNH2MAPTLMNASMN1; SMN2HSD17B10 | |
| SCHEMBL4252609 | 0.89 | KCNH2 (0.73) | KCNH2MAPTLMNACACNA1GHTR7 | |
| SCHEMBL2016318 | 0.89 | KCNH2 (0.73) | KCNH2MAPTLMNACACNA1GHTR7 | |
| SCHEMBL2019829 | 0.88 | KCNH2 (0.83) | KCNH2MAPTLMNAHTR7ALDH1A1 | |
| SCHEMBL2019833 | 0.88 | KCNH2 (0.83) | KCNH2MAPTLMNAHTR7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079852-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | LIOTTA DENNIS C (US) | 2014-01-30 | — | — | US | disclosed |
| US-8420680-B2 | NMDA receptor antagonists for neuroprotection | EMORY UNIVERSITY (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | EMORY UNIVERSITY | 2011-06-30 | — | — | US | disclosed |
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | EMORY UNIVERSITY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253710-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 137/4885MAPT 2477/4885LMNA 4281/4885 |
| US-20110160223-A1 | NMDA Receptor Antagonists for the Treatment of Neuropsychiatric Disorders | GRIN2A, GRIN2B, GRIN1 | KCNH2 469/4885MAPT 704/4885LMNA 4579/4885 |
| US-20140031363-A1 | NMDA Receptor Antagonists for Neuroprotection | GRIN1, GRIN2C, GRIK1 | KCNH2 135/4885MAPT 2536/4885LMNA 4298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.